Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge

Philip R. Johnson, David C. Montefiori, Simoy Goldstein, Tiffany E. Hamm, Jiying Zhou, Svetlana Kltov, Nancy Haigwood, Lynda Mlsher, Wllliam T. London, John L. Gerin, Anthony Allison, Robert H. Purcell, Robert M. Chancck, Vanessa M. Hirsch

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

We tested the ability of macaques vaccinated with inactivated whole simian immunodeficiency virus (SIV) to resist challenge with either homologous or heterologous cell-free uncloned SIV administered by the intravenous route. The vaccine virus was derived from a proviral DNA clone and thus was considered genetically homogeneous. Sixteen macaques received either hepatitis B surface antigen (n = 6) or the inactivated whole-SIV vaccine (n = 10) at weeks 0, 4, and 49 of the study. All SIV vaccine recipients developed high levels of homologous and heterologous neutralizing antibodies in response to vaccination. At the time of challenge (week 53), vaccinees were further stratified to receive either homologous (n = 10) or heterologous (n = 6) uncloned live SIV. The envelope glycoproteins of the homologous and heterologous challenge viruses were 94% and 81% identical to the vaccine virus, respectively. Regardless of challenge inoculum, all vaccinees in the control group (hepatitis B surface antigen) became infected, whereas all SIV vaccinees were protected against detectable infection. These data support the concept that an efficacious vaccine for HIV might be possible, and suggest that genetic variation of HIV might not be an insurmountable obstacle for vaccine development.

Original languageEnglish (US)
Pages (from-to)2175-2179
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume89
Issue number6
StatePublished - 1992
Externally publishedYes

Fingerprint

Simian Immunodeficiency Virus
Neutralizing Antibodies
Vaccines
Clone Cells
Viruses
DNA
Macaca
Hepatitis B Surface Antigens
Heterophile Antibodies
AIDS Vaccines
Antibody Formation
Glycoproteins
Vaccination
HIV
Control Groups
Infection

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. / Johnson, Philip R.; Montefiori, David C.; Goldstein, Simoy; Hamm, Tiffany E.; Zhou, Jiying; Kltov, Svetlana; Haigwood, Nancy; Mlsher, Lynda; London, Wllliam T.; Gerin, John L.; Allison, Anthony; Purcell, Robert H.; Chancck, Robert M.; Hirsch, Vanessa M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 89, No. 6, 1992, p. 2175-2179.

Research output: Contribution to journalArticle

Johnson, PR, Montefiori, DC, Goldstein, S, Hamm, TE, Zhou, J, Kltov, S, Haigwood, N, Mlsher, L, London, WT, Gerin, JL, Allison, A, Purcell, RH, Chancck, RM & Hirsch, VM 1992, 'Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge', Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 6, pp. 2175-2179.
Johnson, Philip R. ; Montefiori, David C. ; Goldstein, Simoy ; Hamm, Tiffany E. ; Zhou, Jiying ; Kltov, Svetlana ; Haigwood, Nancy ; Mlsher, Lynda ; London, Wllliam T. ; Gerin, John L. ; Allison, Anthony ; Purcell, Robert H. ; Chancck, Robert M. ; Hirsch, Vanessa M. / Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. In: Proceedings of the National Academy of Sciences of the United States of America. 1992 ; Vol. 89, No. 6. pp. 2175-2179.
@article{209f94014ff84d3fb939e13b4e4cc3af,
title = "Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge",
abstract = "We tested the ability of macaques vaccinated with inactivated whole simian immunodeficiency virus (SIV) to resist challenge with either homologous or heterologous cell-free uncloned SIV administered by the intravenous route. The vaccine virus was derived from a proviral DNA clone and thus was considered genetically homogeneous. Sixteen macaques received either hepatitis B surface antigen (n = 6) or the inactivated whole-SIV vaccine (n = 10) at weeks 0, 4, and 49 of the study. All SIV vaccine recipients developed high levels of homologous and heterologous neutralizing antibodies in response to vaccination. At the time of challenge (week 53), vaccinees were further stratified to receive either homologous (n = 10) or heterologous (n = 6) uncloned live SIV. The envelope glycoproteins of the homologous and heterologous challenge viruses were 94{\%} and 81{\%} identical to the vaccine virus, respectively. Regardless of challenge inoculum, all vaccinees in the control group (hepatitis B surface antigen) became infected, whereas all SIV vaccinees were protected against detectable infection. These data support the concept that an efficacious vaccine for HIV might be possible, and suggest that genetic variation of HIV might not be an insurmountable obstacle for vaccine development.",
author = "Johnson, {Philip R.} and Montefiori, {David C.} and Simoy Goldstein and Hamm, {Tiffany E.} and Jiying Zhou and Svetlana Kltov and Nancy Haigwood and Lynda Mlsher and London, {Wllliam T.} and Gerin, {John L.} and Anthony Allison and Purcell, {Robert H.} and Chancck, {Robert M.} and Hirsch, {Vanessa M.}",
year = "1992",
language = "English (US)",
volume = "89",
pages = "2175--2179",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "6",

}

TY - JOUR

T1 - Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge

AU - Johnson, Philip R.

AU - Montefiori, David C.

AU - Goldstein, Simoy

AU - Hamm, Tiffany E.

AU - Zhou, Jiying

AU - Kltov, Svetlana

AU - Haigwood, Nancy

AU - Mlsher, Lynda

AU - London, Wllliam T.

AU - Gerin, John L.

AU - Allison, Anthony

AU - Purcell, Robert H.

AU - Chancck, Robert M.

AU - Hirsch, Vanessa M.

PY - 1992

Y1 - 1992

N2 - We tested the ability of macaques vaccinated with inactivated whole simian immunodeficiency virus (SIV) to resist challenge with either homologous or heterologous cell-free uncloned SIV administered by the intravenous route. The vaccine virus was derived from a proviral DNA clone and thus was considered genetically homogeneous. Sixteen macaques received either hepatitis B surface antigen (n = 6) or the inactivated whole-SIV vaccine (n = 10) at weeks 0, 4, and 49 of the study. All SIV vaccine recipients developed high levels of homologous and heterologous neutralizing antibodies in response to vaccination. At the time of challenge (week 53), vaccinees were further stratified to receive either homologous (n = 10) or heterologous (n = 6) uncloned live SIV. The envelope glycoproteins of the homologous and heterologous challenge viruses were 94% and 81% identical to the vaccine virus, respectively. Regardless of challenge inoculum, all vaccinees in the control group (hepatitis B surface antigen) became infected, whereas all SIV vaccinees were protected against detectable infection. These data support the concept that an efficacious vaccine for HIV might be possible, and suggest that genetic variation of HIV might not be an insurmountable obstacle for vaccine development.

AB - We tested the ability of macaques vaccinated with inactivated whole simian immunodeficiency virus (SIV) to resist challenge with either homologous or heterologous cell-free uncloned SIV administered by the intravenous route. The vaccine virus was derived from a proviral DNA clone and thus was considered genetically homogeneous. Sixteen macaques received either hepatitis B surface antigen (n = 6) or the inactivated whole-SIV vaccine (n = 10) at weeks 0, 4, and 49 of the study. All SIV vaccine recipients developed high levels of homologous and heterologous neutralizing antibodies in response to vaccination. At the time of challenge (week 53), vaccinees were further stratified to receive either homologous (n = 10) or heterologous (n = 6) uncloned live SIV. The envelope glycoproteins of the homologous and heterologous challenge viruses were 94% and 81% identical to the vaccine virus, respectively. Regardless of challenge inoculum, all vaccinees in the control group (hepatitis B surface antigen) became infected, whereas all SIV vaccinees were protected against detectable infection. These data support the concept that an efficacious vaccine for HIV might be possible, and suggest that genetic variation of HIV might not be an insurmountable obstacle for vaccine development.

UR - http://www.scopus.com/inward/record.url?scp=0026549513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026549513&partnerID=8YFLogxK

M3 - Article

C2 - 1549578

AN - SCOPUS:0026549513

VL - 89

SP - 2175

EP - 2179

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 6

ER -